Inqovi (decitabine/cedazuridine): Uses, Side Effects, Interactions, Pictures, Warnings & Dosing

Medical note: This article is for general education and should not replace instructions from an oncologist, oncology pharmacist, or cancer care team. Inqovi is a prescription cancer medicine with potentially serious risks, and treatment plans must be individualized.

Inqovi is one of those medications with a name that sounds as though it belongs on a futuristic spaceship, but its job is firmly grounded in modern blood-cancer care. It combines decitabine and cedazuridine in one oral tablet, offering an alternative to receiving decitabine by IV infusion for many eligible adults with myelodysplastic syndromes.

That does not mean Inqovi is a casual “take it and forget it” pill. It is a cancer treatment that can lower blood counts, increase infection and bleeding risks, and require close laboratory monitoring. Still, for people whose care team recommends it, the ability to take treatment at home for part of each cycle can be a meaningful convenience. Fewer infusion-center visits may sound small on paper, but anyone who has tried to schedule life around medical appointments knows that small things can become very big things.

What Is Inqovi?

Inqovi is a fixed-dose oral medication containing 35 mg of decitabine and 100 mg of cedazuridine. Decitabine is a hypomethylating agent, sometimes called an epigenetic therapy. Cedazuridine is included because it helps prevent decitabine from being broken down too quickly in the digestive tract and liver.

In plain English, decitabine needs help surviving the trip from the stomach into the bloodstream. Cedazuridine acts like the bodyguard at the door, helping more decitabine remain available after the tablet is swallowed. This allows the oral combination to provide decitabine exposure similar to the standard IV decitabine regimen used in the clinical studies.

Decitabine works by interfering with abnormal DNA methylation. Cancer cells and unhealthy bone marrow cells can use abnormal methylation patterns almost like a “do not disturb” sign on genes that should regulate growth and cell development. Decitabine may help restore activity in some of those genes, encouraging abnormal cells to mature differently or die.

What Is Inqovi Used For?

Inqovi is approved in the United States for adults with certain myelodysplastic syndromes (MDS), including chronic myelomonocytic leukemia, or CMML. MDS is a group of bone marrow disorders in which the marrow does not make enough healthy blood cells or produces cells that do not function normally.

The medication may be used for adults with previously treated or untreated MDS, including de novo MDS and secondary MDS. The approved indication includes several older French-American-British classification categories and people with intermediate-1, intermediate-2, or high-risk prognostic groups.

In May 2026, the FDA also approved Inqovi in combination with venetoclax for adults with newly diagnosed acute myeloid leukemia, or AML, who are age 75 or older or have medical conditions that make intensive induction chemotherapy unsuitable.

Why MDS and AML Can Cause Similar Concerns

MDS and AML can affect the bone marrow’s ability to make healthy blood cells. That may lead to anemia, fatigue, shortness of breath, infections, easy bruising, or bleeding. Inqovi can also lower blood counts, particularly during treatment. That is why lab results are not background paperwork; they are one of the main ways the care team decides whether treatment should continue, pause, or change.

Inqovi Pictures: What Does the Tablet Look Like?

A tablet’s appearance can help with identification, but it should never be the only safety check. Do not use a random image online as proof that a pill is correct. Packaging, lighting, camera filters, and look-alike medications can make the internet surprisingly unreliable at pill recognition. When in doubt, ask the dispensing pharmacy or oncology team before taking a dose.

Inqovi Dosing and How It Is Taken

The usual Inqovi schedule is straightforward in theory and highly specific in practice: one tablet by mouth once daily on Days 1 through 5 of a 28-day cycle. The remaining days of the cycle are generally treatment-free days for Inqovi unless the oncology team gives different instructions.

Standard Inqovi Dose for MDS or CMML

For MDS or CMML, the recommended regimen is one Inqovi tablet once daily for five days during each 28-day cycle. Treatment is generally continued for at least four cycles, provided it is tolerated and the disease has not progressed. A response may take longer than four cycles, so early treatment can require patience. Cancer therapy is rarely a microwave dinner; it may need time before the results become clear.

Inqovi Dose With Venetoclax for AML

For the FDA-approved AML combination, Inqovi is also taken once daily on Days 1 through 5 of each 28-day cycle, together with venetoclax according to the oncology team’s plan. Inqovi and venetoclax should not be taken at the same time. Inqovi should be taken at least two hours before or two hours after venetoclax.

Administration Rules That Matter

• Take Inqovi on an empty stomach, at least two hours before or two hours after food.
• Take it at about the same time each day.
• Swallow the tablet whole. Do not cut, crush, chew, or split it.
• Do not substitute an IV decitabine product for Inqovi within the same treatment cycle unless the oncology team specifically directs it.
• Keep the medicine in its original blister packaging until it is time to take the dose.
• Do not share Inqovi with anyone else, even another person with the same diagnosis.

What If a Dose Is Missed or Vomited?

If a dose is missed but remembered within 12 hours of the usual time, the patient should take it as soon as possible and then resume the normal schedule. If more than 12 hours have passed, the missed dose should not be doubled or “made up” without instructions from the cancer care team.

If vomiting occurs after taking Inqovi, do not take an extra tablet. Take the next scheduled dose at the usual time. The oncology team may prescribe anti-nausea medicine before doses when appropriate.

Common Inqovi Side Effects

Inqovi can affect healthy cells along with abnormal bone marrow cells. Some side effects are manageable with monitoring and supportive care, while others need urgent medical attention. The most important risk is myelosuppression, meaning a drop in blood cell counts.

Low Blood Counts

Inqovi may lower white blood cells, neutrophils, red blood cells, and platelets. This can raise the risk of infection, anemia, fatigue, bleeding, or bruising. Low counts may happen because of the disease itself, the treatment, or both. The care team uses complete blood count testing to sort out that complicated puzzle.

Common or clinically important blood-related effects can include:

• Neutropenia or low infection-fighting white blood cells
• Leukopenia or a low overall white blood cell count
• Thrombocytopenia or low platelets
• Anemia or a low red blood cell count
• Febrile neutropenia, meaning fever with a low neutrophil count
• Easy bruising, unusual bleeding, or bleeding that takes longer to stop

Other Common Side Effects

Other reported Inqovi side effects may include fatigue, constipation, nausea, diarrhea, decreased appetite, mouth or throat sores, muscle pain, joint pain, rash, dizziness, headache, cough, swelling in the arms or legs, shortness of breath, upper respiratory infections, pneumonia, and changes in liver test results.

For people taking Inqovi with venetoclax for AML, side effects may also include infection, sepsis, abdominal pain, irregular heart rhythm, kidney problems, and tumor lysis syndrome. The combination is not simply “Inqovi plus one more pill.” It is a carefully managed cancer regimen that requires frequent monitoring.

Serious Warnings: When to Contact the Cancer Care Team

Because low blood counts can become serious, patients should follow their oncology team’s instructions about when to call. A fever, chills, feeling suddenly unwell, worsening cough, sore throat, new shortness of breath, painful urination, confusion, unusual bleeding, black stools, or rapidly spreading bruising should never be shrugged off as “probably nothing.”

Call the cancer care team promptly for symptoms of infection, anemia, or bleeding. The team may recommend urgent evaluation, blood tests, antibiotics, transfusions, treatment delays, dose reductions, or other supportive care depending on the situation.

Pregnancy, Breastfeeding, and Fertility

Inqovi can harm an unborn baby. People who can become pregnant should have pregnancy status checked before starting treatment and use effective contraception during treatment and for six months after the final dose. Males with partners who can become pregnant should use effective contraception during treatment and for three months after the final dose.

Breastfeeding is not recommended during treatment or for two weeks after the final dose. Inqovi may also affect fertility, particularly male fertility, and it is not known whether those effects are reversible. Fertility preservation questions are best discussed before treatment starts whenever possible.

Inqovi Drug Interactions

Inqovi has an important interaction concern because cedazuridine blocks an enzyme called cytidine deaminase, or CDA. Taking Inqovi with other medications metabolized by CDA may increase exposure to those medicines and raise their toxicity risk. The prescribing information advises avoiding this combination.

That is why every medication list matters. Patients should tell the oncology team and pharmacist about prescription drugs, over-the-counter products, vitamins, herbal products, supplements, and new medications prescribed by other clinicians. A complete list is much more useful than trying to remember drug names from memory while sitting under fluorescent clinic lights.

Patients should also tell their team about kidney problems, liver problems, current infections, recent vaccines, planned dental procedures, and any history of unusual medication reactions. Inqovi has not been fully studied in people with severe kidney impairment, end-stage kidney disease, or moderate to severe liver impairment.

How Dose Changes and Monitoring Work

Inqovi dosing is not always fixed forever. If blood counts are slow to recover or if serious side effects occur, the oncology team may delay the next cycle or reduce the number of treatment days. For MDS or CMML, dose reductions may change the schedule from five days to four days, then three days, or another adjusted pattern if myelosuppression persists.

Patients should never make those changes independently. Skipping doses, restarting early, or taking extra tablets can create real risks. Cancer treatment is not a choose-your-own-adventure book; the medication calendar should come directly from the oncology team.

Practical Tips for Taking Inqovi Safely

• Use a calendar, medication tracker, or phone reminder for Days 1 through 5.
• Keep a current medication list in a wallet or phone.
• Ask the care team for a written fever and infection plan.
• Use gentle oral care if mouth sores or bleeding gums become a problem.
• Ask before taking pain relievers, cold medicines, supplements, or herbal remedies.
• Store Inqovi at room temperature in the original packaging and keep it away from children and pets.
• Ask a pharmacist or oncology nurse how to dispose of unused tablets safely.

What the Inqovi Treatment Experience Can Look Like

The following examples are composite educational scenarios, not real patient stories and not a substitute for personal medical advice.

For many people, the first Inqovi cycle feels less like a dramatic movie scene and more like learning the operating manual for a very serious new appliance. There is the timing rule around food, the five-day schedule, the blood-test appointments, the medication list, and the quiet realization that “taking a pill at home” does not mean “treatment requires no planning.” The oral format can reduce infusion visits, but it also places more responsibility on the patient and caregiver to follow the schedule accurately.

One common experience is that fatigue can be hard to interpret. A person may wonder whether tiredness comes from MDS, AML, anemia, disrupted sleep, treatment, stress, or the fact that life has suddenly turned into a spreadsheet of appointments. Often, the honest answer is that several factors may be involved. This is where blood counts and symptom tracking become useful. Writing down fatigue, dizziness, shortness of breath, appetite changes, bowel changes, and temperatures can make clinic visits more productive.

Another major adjustment is learning to treat fever differently. A fever during low blood counts is not automatically a minor cold. People receiving Inqovi may be told to contact their care team promptly rather than waiting to see whether symptoms improve by morning. That can feel inconvenient or overly cautious at first, but it is an important part of avoiding serious infections. The safest plan is the one provided by the oncology team, including where to call after hours and when to seek urgent care.

Food timing can also require a small lifestyle redesign. Since Inqovi is taken on an empty stomach, some people find it easier to choose a consistent daily routine, such as taking it early in the morning before breakfast or later in the evening well after dinner. The best time is not necessarily the most fashionable time; it is the time that fits the prescribed fasting window and is easiest to repeat reliably.

Caregivers often become the unofficial quality-control department. They may help review the calendar, check whether the blister card has been opened, organize transportation for lab visits, and watch for symptoms the patient might minimize. That support is valuable, but it should not turn into nonstop surveillance. A simple shared checklist can reduce anxiety without making the household feel like a tiny hospital ward.

It is also common for treatment plans to change. A delayed cycle or adjusted dose does not automatically mean treatment has failed. Inqovi can lower blood counts, and the team may pause or modify therapy to allow recovery or manage complications. Those decisions are part of safe cancer care, not a sign that someone has “done treatment wrong.”

Finally, the emotional side deserves space. Oral cancer treatment can look deceptively ordinary because the medicine comes in a blister pack rather than an IV bag. But the diagnosis, testing, uncertainty, and side effects can still be exhausting. Support from family, oncology social workers, support groups, counselors, and the medical team can make the process more manageable. No one earns extra points for trying to navigate cancer treatment alone.

Conclusion

Inqovi combines decitabine and cedazuridine in an oral treatment for eligible adults with MDS, CMML, and, when used with venetoclax, certain newly diagnosed AML cases. Its at-home tablet format can be convenient, but it remains a potent cancer medicine that requires careful timing, frequent blood-count monitoring, medication review, infection awareness, and close communication with an oncology team.

The most important takeaway is simple: take Inqovi exactly as prescribed, do not improvise missed-dose or dose-reduction decisions, and report signs of infection, bleeding, or severe fatigue promptly. A good cancer care plan is not just the medicine itself; it is the medicine plus the monitoring, the communication, and the support around it.